===== AI Summary =====
A 36-year-old woman with AMH 2.3 ng/mL underwent IVF due to bilateral tubal factor. The first egg retrieval yielded 10 MII oocytes, forming 6 usable embryos. Two fresh Day 3 embryos were transferred, resulting in no implantation. The remaining 4 embryos underwent blastocyst culture, yielding 2 blastocysts. One frozen-thawed blastocyst was transferred, resulting in a biochemical pregnancy. After two failures, the patient's primary concern was not the protocol itself, but: Where exactly does the problem lie?
This case is not uncommon in clinical practice. After IVF failure, the most urgent need is to figure out "why it failed," not "when to try again." The following systematically breaks down the management strategy after IVF failure from a clinical decision-making pathway.
===== 2 Secondary Heading =====I. Classification of Direct Causes of IVF Failure
From the complete chain of embryo development and implantation, the causes of failure can be categorized into the following six dimensions:
| Cause Category | Common Specific Factors | Clinical Proportion (Reference) |
|---|---|---|
| Embryo Factors | Chromosomal aneuploidy, severe fragmentation, developmental arrest, mitochondrial dysfunction | 40–60% |
| Endometrial Factors | Chronic endometritis, thin endometrium, endometrial polyps, adhesions, adenomyosis | 15–25% |
| Immune-Coagulation Factors | Antiphospholipid antibody syndrome, abnormal NK cells, thyroid antibodies, coagulation dysfunction | 10–20% |
| Endocrine Factors | Luteal phase deficiency, thyroid dysfunction, hyperprolactinemia | 5–10% |
| Anatomical Factors | Uterine septum, intrauterine adhesions, hydrosalpinx reflux | 5–10% |
| Other Factors | High sperm DNA fragmentation, chronic stress, abnormal BMI, vitamin D deficiency | 5–10% |
It is important to note that most failures result from a combination of multiple factors, and the proportion attributed to a single cause is often overestimated.
===== 3 Secondary Heading =====II. Why Does IVF Failure Occur: In-depth Attribution from a Physician's Perspective
2.1 Embryonic Chromosomal Abnormalities are the Primary Cause
Female age is the strongest variable affecting the rate of chromosomally normal embryos. The euploidy rate in embryos is approximately 50–60% for women under 35, dropping to 20–30% for those over 40. Even embryos with high morphological scores may have chromosomal abnormalities. PGT-A (Preimplantation Genetic Testing for Aneuploidy) can screen for euploid embryos to some extent but does not solve all problems.
2.2 Displacement of the Window of Endometrial Receptivity
Approximately 20–30% of patients with recurrent implantation failure have a displaced window of endometrial receptivity, meaning the standard transfer timing is not their optimal implantation window. The ERA (Endometrial Receptivity Array) test can identify the personalized window, but it still has the potential for false negatives and false positives and has requirements for the cycle protocol.
2.3 Chronic Endometritis
The positive rate of chronic endometritis (CE) in the recurrent implantation failure population can reach 30–40%. CD138 immunohistochemical staining is the gold standard for diagnosis, but routine hysteroscopy can only detect about 50% of cases. After antibiotic treatment, implantation rates can improve in some patients.
2.4 Immune-Coagulation Factors are Overinterpreted
There is a phenomenon of overdiagnosis and overtreatment of immune factors in clinical practice. Indicators such as positive thyroid antibodies, positive antiphospholipid antibodies, and elevated NK cells need to be assessed in the context of the patient's overall condition; not all positive results require intervention. Anticoagulation therapy and immunomodulatory therapy should be used only when there are clear indications.
===== 4 Secondary Heading =====III. Strategy Differences Across Age Groups
| Age Group | Core Issue | Priority Investigation Direction | Key Decision Points |
|---|---|---|---|
| ≤35 years | Relatively fewer embryo factors; higher proportion of endometrial/immune factors | Hysteroscopy, initial immune-coagulation screening, sperm DNA fragmentation | Consider another stimulation or frozen embryo transfer; PGT is not urgently needed |
| 36–39 years | Risk of embryonic chromosomal abnormalities significantly increases | PGT-A (if usable embryos available), ERA, endometrial microbiome | Prioritize investigation of embryo factors, then consider maternal factors |
| ≥40 years | Low embryo euploidy rate, declining ovarian reserve | Cumulative oocyte retrieval strategy, PGT-A, mitochondrial DNA assessment | Prepare for multiple cycles, manage expectations appropriately |
IV. Most Easily Overlooked Details
- Timing of Hysteroscopy: Not everyone needs a hysteroscopy after failure, but for those with recurrent implantation failure (≥2 times) or a history of uterine surgery, it is recommended to complete hysteroscopy + endometrial biopsy (CD138) before the next transfer.
- Thyroid Function Stability: Controlling TSH below 2.5 mIU/L is beneficial for implantation, but excessive adjustment leading to hyperthyroidism should be avoided.
- Vitamin D Levels: Vitamin D deficiency is associated with implantation failure. Testing and supplementation to the normal range (≥30 ng/mL) is recommended.
- Sperm DNA Fragmentation Index (DFI): DFI > 30% may affect embryo developmental potential, even if routine semen parameters are normal. Elevated DFI can be improved through antioxidant therapy or testicular sperm extraction.
- Luteal Phase Support Protocol: The bioavailability of intramuscular progesterone and vaginal gel varies individually. For patients with recurrent implantation failure, combined administration or a change in formulation can be considered.
V. Most Common Decision-Making Pitfalls
- Blindly pursuing immunotherapy: Using immunosuppressants like prednisone, hydroxychloroquine, or adalimumab without completing a systematic investigation is not only unhelpful but may also increase the risk of infection and metabolic issues.
- Repeatedly transferring embryos from the same batch: If a batch of embryos is known to be all Day 3 embryos of average quality, continuing to transfer them without adjusting the stimulation protocol or culture strategy offers limited improvement in success rates.
- Over-reliance on PGT-A: PGT-A cannot detect all chromosomal abnormalities and carries a risk of missing mosaicism. For patients with low ovarian reserve, PGT-A may result in no embryos available for transfer.
- Neglecting the male factor: In cases of recurrent implantation failure, the male evaluation is often underemphasized. Sperm DFI, Y-chromosome microdeletions, and seminal plasma oxidative stress should be included in the investigation.
- Underestimating psychological stress: Persistent anxiety and sleep disorders can affect endometrial receptivity via the cortisol axis; psychological intervention may be necessary.
VI. Practical Timeline: Arrangements from Failure to the Next Transfer
6.1 Step One: Systematic Attribution (1–2 months)
- Weeks 1–2: Review the details of the previous cycle with the reproductive specialist (stimulation protocol, embryo grading, transfer procedure, luteal phase support).
- Weeks 2–4: Complete hysteroscopy + endometrial biopsy (CD138), initial immune-coagulation screening (antiphospholipid antibodies, thyroid antibodies, NK cells, coagulation panel), vitamin D, TSH, sperm DFI (male partner).
- Weeks 4–8: Targeted management based on results. If surplus embryos are available, consider PGT-A testing. If another stimulation is needed, formulate a new protocol.
6.2 Step Two: Targeted Intervention (1–3 months)
- Chronic endometritis: Antibiotic therapy for 14–21 days, recheck endometrial microbiome.
- Thin endometrium: Estrogen supplementation, intrauterine G-CSF infusion, improve endometrial blood flow.
- Immune abnormalities: Medication based on rheumatology/immunology consultation; avoid self-medication.
- Embryo factors: Change stimulation protocol (e.g., PPOS, mild stimulation), add growth hormone, optimize blastocyst culture strategy.
6.3 Step Three: Formulate the Next Cycle Protocol (1–2 months)
- Frozen embryo transfer: Choose natural cycle, artificial cycle, or stimulated cycle based on endometrial response and hormone levels.
- Fresh transfer: Only choose when there is sufficient evidence of an advantage in the fresh cycle.
- Number of embryos to transfer: Single blastocyst transfer is generally recommended to reduce the risk of multiple pregnancies.
VII. Interpretation of Key Diagnostic Tests
| Test Item | Reference Range | Impact on Decision-Making |
|---|---|---|
| AMH | ≥1.2 ng/mL (age-adjusted) | Determines the intensity of the stimulation protocol and expected number of cycles |
| TSH | 0.5–2.5 mIU/L | If out of range, endocrine adjustment is needed before transfer |
| CD138+ Plasma Cells | Negative or ≤5/HPF | Positive requires antibiotic therapy |
| Sperm DNA Fragmentation Index (DFI) | ≤15% good; 15–30% moderate; >30% intervention recommended | If elevated, consider antioxidants or testicular sperm extraction |
| Vitamin D | ≥30 ng/mL | If deficient, supplement to normal range |
| Antiphospholipid Antibodies (aPL) | Negative | Positive requires anticoagulation therapy |
VIII. Frequently Asked Questions
8.1 How long after IVF failure can I have another transfer?
If there are no special complications (e.g., OHSS, infection), an interval of 1–2 normal menstrual cycles is generally recommended. This time is used for cause investigation and physical recovery. For older patients (≥38 years) with normal ovarian reserve, the interval can be appropriately shortened.
8.2 Do I need a hysteroscopy?
Not mandatory after every failure. However, it is strongly recommended in the following situations: ≥2 failed transfers, history of uterine surgery, ultrasound suggesting uneven endometrial echo or suspected adhesions, recurrent biochemical pregnancies.
8.3 Is immunotherapy useful?
Immunotherapy is effective for definitively diagnosed autoimmune diseases or antiphospholipid antibody syndrome. However, "empirical" immunotherapy without indications is not recommended due to insufficient evidence.
8.4 Should I change hospitals or doctors?
If the current center has completed a systematic investigation and provided a clear next-step plan, switching solely due to failure is not recommended. However, if there are communication barriers or the center lacks necessary testing capabilities (e.g., ERA, PGT, hysteroscopy), a referral can be considered.
8.5 Is there still a chance after IVF failure for advanced maternal age (≥42 years)?
The chance is closely related to ovarian reserve, embryo euploidy rate, and uterine conditions. It is recommended to attempt ≤3 stimulation cycles, with a cumulative live birth rate of approximately 10–20% (fluctuating with age and ovarian function). Using PGT-A can reduce the miscarriage rate but does not significantly increase the cumulative live birth rate.
===== 10 Secondary Heading =====IX. Management of Special Situations
- Recurrent biochemical pregnancy: Prioritize investigation for chronic endometritis, chromosomal abnormalities (PGT on surplus embryos), thyroid function, and antiphospholipid antibodies.
- Recurrent early miscarriage (within 12 weeks of gestation): Recommend peripheral blood karyotype analysis for both partners and chromosomal microarray analysis (CMA) of the miscarriage tissue.
- Recurrent failure with Day 3 embryo transfers: Consider switching to a blastocyst culture strategy or adjusting the stimulation protocol to improve oocyte quality.
- Concurrent adenomyosis: Can try GnRH-a pretreatment for 2–4 months, or consider surgical lesion reduction before transfer.
#what to do after IVF failure #failure cause analysis #second transfer strategy #hysteroscopy #immune factor investigation #strategies for advanced maternal age IVF #PGT-A consultation
Comments (0)